PTC Therapeutics, Inc.
PTCT
Positions held
Your positionsPTCT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- PTC Therapeutics operates in a competitive biotechnology sector with a focus on innovative therapies, positioning itself well against other companies in the industry.
- Revenue increased by 32% compared to the prior quarter, reaching $361 million.
- Gross margin improved to 94.5%, up from 89.7% in the previous quarter.
- The company's financials show a concerning trend with a negative profit margin and significant operating losses, indicating potential challenges ahead.
- The net income for 2026-Q1 was -$2.809 million, reflecting ongoing financial struggles.
- The overall score indicates a 'Sell' signal with a score of -12.00, suggesting bearish sentiment among investors.
Fundamentals
| Market cap | $5.22B | Enterprise value | $6.01B | Trailing P/E | — | Forward P/E | 26.40 |
| PEG | — | Price / book | -31.52 | Beta | 0.49 | Dividend yield | 0.00% |
| Revenue growth | 101.5% | Earnings growth | — | Gross margin | 50.0% | Operating margin | 41.3% |
| Profit margin | -3.8% | ROE | — | ROA | 2.5% | Debt / equity | — |
| Current ratio | 3.39 | Free cash flow | -$286.80M | Analyst recommendation | buy | Mean target | $101.07 |
| 52w high | $90.87 | 52w low | $61.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M |
| Op margin | 41.3% | 16.8% | -49.6% | 1.7% | -19.5% |
| Net income | $83.5M | -$2.8M | -$135M | $15.9M | -$64.8M |
| Gross margin | 94.5% | 89.7% | 95.8% | 92.5% | 93.6% |
| Gross profit | $341M | $245M | $158M | $195M | $167M |
| Operating income | $149M | $45.9M | -$81.6M | $3.5M | -$34.9M |
- Revenue +32% vs prior quarter ($361M vs $273M).
- Gross margin 94.5% (was 89.7% prior quarter).
- Operating margin expanded to 41.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $1.7B | $807M | $938M | $699M |
| Op margin | 49.5% | -18.2% | -37.3% | -63.0% |
| Net income | $683M | -$363M | -$627M | -$559M |
| Gross margin | 97.3% | 92.9% | 93.0% | 93.6% |
| Gross profit | $1.7B | $749M | $872M | $654M |
| Operating income | $857M | -$147M | -$349M | -$440M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating
2026-10-07 · PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says
2026-10-06 · Is PTC Stock Increasing Your Market Risk?
2026-09-30 · Which Gives You More Of Hard-To-Replace Software, PTC Or Fair Isaac?
2026-09-28 · 2026 Philadelphia ORBIE Awards Honor Top Technology and Security Executives in Philadelphia
2026-09-25 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-21 · PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease
2026-09-21 · PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
2026-09-20 · PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress
2026-09-18 · ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
2026-08-27 · PTC Therapeutics to Participate in Upcoming Investor Conferences
Price (daily)
Full chart · RSI · MACD · patterns